1.
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. [PubMed: 25530442]. [PubMed Central: PMC4340604].
2.
Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385(9973):1124-35. doi: 10.1016/S0140-6736(14)62401-6. [PubMed: 25687730]. [PubMed Central: PMC4878852].
3.
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. doi: 10.1001/jama.2012.144878. [PubMed: 23268517].
4.
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014;61(1 Suppl):S58-68. doi: 10.1016/j.jhep.2014.07.012. [PubMed: 25443346].
5.
Hudson LE, Allen RL. Leukocyte Ig-like receptors - a model for MHC class I disease associations. Front Immunol. 2016;7:281. doi: 10.3389/fimmu.2016.00281. [PubMed: 27504110]. [PubMed Central: PMC4959025].
6.
Miki D, Ochi H, Takahashi A, Hayes CN, Urabe Y, Abe H, et al. HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: A genome-wide association study. PLoS One. 2013;8(12). e84226. doi: 10.1371/journal.pone.0084226. [PubMed: 24376798]. [PubMed Central: PMC3871580].
7.
Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. [PubMed: 22300469].
8.
Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther. 2013;37(10):921-36. doi: 10.1111/apt.12300. [PubMed: 23557103].
9.
Huang P, Dong L, Lu X, Zhang Y, Chen H, Wang J, et al. Genetic variants in antigen presentation-related genes influence susceptibility to hepatitis C virus and viral clearance: A case control study. BMC Infect Dis. 2014;14:716. doi: 10.1186/s12879-014-0716-8. [PubMed: 25528575]. [PubMed Central: PMC4279674].
10.
Gheorghe L, Rugina S, Dumitru IM, Franciuc I, Martinescu A, Balas I. HLA class II alleles in Romanian patients with chronic hepatitis C. Germs. 2015;5(2):44-9. doi: 10.11599/germs.2015.1070. [PubMed: 26097834]. [PubMed Central: PMC4472190].
11.
Susser S, Herrmann E, Lange C, Hamdi N, Muller T, Berg T, et al. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C. PLoS One. 2014;9(11). e112592. doi: 10.1371/journal.pone.0112592. [PubMed: 25393304]. [PubMed Central: PMC4231027].
12.
Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML. Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy. Int J Infect Dis. 2015;30:91-7. doi: 10.1016/j.ijid.2014.09.021. [PubMed: 25462177].
13.
Farag RE, Arafa MM, El-Etreby S, Saudy NS, Eldeek BS, El-Alfy HA, et al. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients. Arch Iran Med. 2013;16(2):68-73. [PubMed: 23360626].
14.
Shaker O, Bassiony H, El Raziky M, El-Kamary SS, Esmat G, El-Ghor AM, et al. Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. Mediators Inflamm. 2013;2013:392746. doi: 10.1155/2013/392746. [PubMed: 23576852]. [PubMed Central: PMC3612450].
15.
Ali A, Nisar M, Ahmad H, Saif N, Idrees M, Bajwa MA. Determination of HCV genotypes and viral loads in chronic HCV infected patients of Hazara Pakistan. Virol J. 2011;8:466. doi: 10.1186/1743-422X-8-466. [PubMed: 21982599]. [PubMed Central: PMC3198714].
16.
Din G, Malik S, Ali I, Ahmed S, Dasti JI. Prevalence of hepatitis C virus infection among thalassemia patients: A perspective from a multi-ethnic population of Pakistan. Asian Pac J Trop Med. 2014;7S1:S127-33. doi: 10.1016/S1995-7645(14)60218-2. [PubMed: 25312106].
17.
Dogra G, Chakravarti A, Kar P, Chawla YK. Polymorphism of tumor necrosis factor-alpha and interleukin-10 gene promoter region in chronic hepatitis C virus patients and their effect on pegylated interferon-alpha therapy response. Hum Immunol. 2011;72(10):935-9. doi: 10.1016/j.humimm.2011.06.008. [PubMed: 21756957].
18.
Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop. 2010;43(3):217-23. doi: 10.1590/S0037-86822010000300001. [PubMed: 20563484].
19.
Fernandez-Arquero M, Caldes T, Casado E, Maluenda C, Figueredo MA, De La Concha EG. Polymorphism within the HLA-DQB1*02 promoter associated with susceptibility to coeliac disease. Eur J Immunogenet. 1998;25(1):1-3. doi: 10.1046/j.1365-2370.1998.00083.x. [PubMed: 9587738].
20.
Samimi-Rad K, Sadeghi F, Amirzargar A, Eshraghian MR, Alavian SM, Rahimnia R. Association of HLA class II alleles with hepatitis C virus clearance and persistence in thalassemia patients from Iran. J Med Virol. 2015;87(9):1565-72. doi: 10.1002/jmv.24211. [PubMed: 25970464].
21.
Ksiaa L, Ayed-Jendoubi S, Sfar I, Gorgi Y, Najjar HA, Abdallah TB, et al. Clearance and persistence of hepatitis C virus in a Tunisian population: Association with HLA class I and class II. Viral Immunol. 2007;20(2):312-9. doi: 10.1089/vim.2006.0060. [PubMed: 17603847].
22.
de Rueda PM, Lopez-Nevot MA, Saenz-Lopez P, Casado J, Martin-Casares A, Palomares P, et al. Importance of host genetic factors HLA and IL28B as predictors of response to pegylated interferon and ribavirin. Am J Gastroenterol. 2011;106(7):1246-54. doi: 10.1038/ajg.2011.82. [PubMed: 21670772].
23.
Romero V, Azocar J, Zuniga J, Clavijo OP, Terreros D, Gu X, et al. Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome. Mol Immunol. 2008;45(9):2429-36. doi: 10.1016/j.molimm.2008.01.002. [PubMed: 18289678]. [PubMed Central: PMC2387047].
24.
Huang P, Zhang Y, Lu X, Xu Y, Wang J, Zhang Y, et al. Association of polymorphisms in HLA antigen presentation-related genes with the outcomes of HCV infection. PLoS One. 2015;10(4). e0123513. doi: 10.1371/journal.pone.0123513. [PubMed: 25874709]. [PubMed Central: PMC4395248].
25.
Qureshi H, Bile KM, Jooma R, Alam SE, Afridi HU. Prevalence of hepatitis B and C viral infections in Pakistan: Findings of a national survey appealing for effective prevention and control measures. East Mediterr Health J. 2010;16 Suppl:S15-23. doi: 10.26719/2010.16.Supp.15. [PubMed: 21495584].
26.
Gul A, Ahmed J, Zahir F, Ali Khan I, Ali I. New patterns of HCV subtypes distribution in the Khyber Pakhtunkhwa province of Pakistan. Braz J Infect Dis. 2016;20(1):107-8. doi: 10.1016/j.bjid.2015.09.007. [PubMed: 26626168].
27.
Arshad A, Ashfaq UA. Epidemiology of hepatitis C infection in Pakistan: Current estimate and major risk factors. Crit Rev Eukaryot Gene Expr. 2017;27(1):63-77. doi: 10.1615/CritRevEukaryotGeneExpr.2017018953. [PubMed: 28436333].
28.
Reker C, Islam KM. Risk factors associated with high prevalence rates of hepatitis C infection in Egypt. Int J Infect Dis. 2014;25:104-6. doi: 10.1016/j.ijid.2014.02.003. [PubMed: 24865321].
29.
Buonomo AR, Scotto R, Pinchera B, Coppola N, Monari C, Macera M, et al. Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. New Microbiol. 2018;41(1):26-9. [PubMed: 29112765].
LEAVE A COMMENT HERE: